“The extraordinary effort to speed the development of treatments and vaccines in response to the COVID-19 pandemic has put into sharp relief the need for the global science community to share scientific data openly. As the world’s largest funder of biomedical research, NIH is addressing this need with a new NIH Policy for Data Management and Sharing. This policy requires researchers to plan prospectively for managing and sharing scientific data generated with NIH funds. This policy also establishes the baseline expectation that data sharing is a fundamental component of the research process, which is in line with NIH’s longstanding commitment to making the research it funds available to the public….”
“Speaking virtually from London to a group of more than 120 NIH employees at a recent NIH Data Science Town Hall sponsored by the Office of Data Science Strategy, Dr. Mark Hahnel said, “To get the most out of science, research data needs to be as open as possible, as closed as necessary.”
For Hahnel, “open as possible” means data that is published openly and well-described. It also means educating researchers on the importance of data-sharing and the tools available to them….”
“In July 2020 the Office of Data Science Strategy (ODSS) at the National Institutes of Health (NIH) completed the NIH Figshare Instance project, a one-year pilot with existing generalist repository Figshare to determine how biomedical researchers may use a generalist repository for sharing and reusing NIH-funded data.
To mark the conclusion of this project, ODSS invited Figshare founder and CEO Mark Hahnel, Ph.D., to share some of the pilot outcomes, his perspective on lessons learned from the project, and his thoughts on the future of data sharing at the NIH Data Science Town Hall, a monthly meeting for NIH employees interested in data science activities across the agency. The recording(link is external) of his presentation is now available. …”
“HuBMAP (the Human BioMolecular Atlas Program) has released its inaugural data for use by the scientific community and the general public. Included in this release are detailed, 3D anatomical data and genetic sequences of healthy tissues from seven organ types, at the level of individual cells as well as many bulk tissue datasets. HuBMAP’s ultimate goal is to provide the framework required for scientists to create a 3D atlas of the human body.
HuBMAP’s tools and maps are openly available for research to accelerate understanding of the relationships between cell and tissue organization and function, as well as human health. Visitors can find the data at portal.hubmapconsortium.org.
HuBMAP is a consortium of 18 diverse collaborative research teams across the United States and Europe. HuBMAP values secure, open sharing and collaboration with other consortia and the wider research community. The consortium is managed by a trans-National Institutes of Health (NIH) working group of staff from the NIH Common Fund; National Heart, Lung, and Blood Institute; National Institute of Biomedical Imaging and Bioengineering; and the National Institute of Diabetes and Digestive and Kidney Diseases….”
“Hundreds of drug companies, medical device manufacturers, and universities owe the public a decade’s worth of missing data from clinical trials, federal officials warned last week.
New rules issued last week in the wake of a federal court ruling in February instructed clinical trial sponsors to submit missing data for trials conducted between 2007 and 2017 “as soon as possible.” For years, many trials conducted during that span have largely been exempted from reporting their data to ClinicalTrials.gov, a public database, meaning a decade of data about approved drugs and medical devices has never been made public.
The court’s ruling, and the federal government’s decision not to appeal it and instead to urge trial sponsors to submit the missing information, represent a major win for transparency advocates, who for years have fought to recover the decadelong gap in publicly available clinical trial data. …
The court ruling, and the resulting change in federal policy, come after years of reporting that has detailed how federal research agencies routinely fail to enforce their own rules regarding clinical trial transparency — which advocates say is critical for the public’s understanding of a given medicines’s safety and efficacy. …”
“SciENcv is a tool managed by the National Institutes of Health (NIH) that allows researchers to create a biographical sketch (biosketch) to submit with their grant proposals for funding from NIH, and it can now also be used when seeking funding from the National Science Foundation (NSF).
As of October 5, 2020 the National Science Foundation (NSF) will require researchers to submit a biosketch that meets specific format requirements as part of their grant proposal. Researchers are encouraged to use SciENcv to create biosketches, as SciENcv offers a NSF-approved tool that is integrated with ORCID. Researchers can connect their ORCID iD with their SciENcv profile in order to transfer data from their ORCID record into SciENcv by clicking a button, rather than having to manually retype all of their information….”
“The National Institutes of Health may own intellectual property that undergirds a leading coronavirus vaccine being developed by Moderna, according to documents obtained by Axios and an analysis from Public Citizen.
Why it matters: Because the federal government has an actual stake in this vaccine, it could try to make the vaccine a free or low-cost public good with wide distribution, if the product turns out to be safe and effective.
The big picture: The NIH mostly funds outside research, but it also often invents basic scientific technologies that are later licensed out and incorporated into drugs that are sold at massive profits. The agency rarely claims ownership stakes or pursues patent rights, but that appears to be different with this coronavirus vaccine….”
“COVID-19 open-access data and computational resources are being provided by federal agencies, including NIH, public consortia, and private entities. These resources are freely available to researchers, and this page will be updated as more information becomes available.
The Office of Data Science Strategy seeks to provide the research community with links to open-access data, computational, and supporting resources. These resources are being aggregated and posted for scientific and public health interests. Inclusion of a resource on this list does not mean it has been evaluated or endorsed by NIH….”
“Recognizing the growing interest in preprints, NLM is today launching the first phase of the NIH Preprint Pilot, which will test the viability of making preprints searchable in PubMed Central (PMC) and, by extension, discoverable in PubMed, starting with COVID-19 preprints reporting NIH-supported research.
To be clear, NLM is not building a preprint server for NIH investigators, nor are we developing a comprehensive preprint discovery resource. Rather, through this pilot, we plan to add a curated collection of preprints from eligible preprint servers to our established literature resources. In doing so, our goal is to improve scholarly communications by accelerating and expanding the findability of NIH research results.
With the encouragement of NIH leadership, NLM has been exploring ways to leverage its literature databases to help accelerate the discoverability and maximize the impact of NIH-supported research via preprints. The planned pilot builds on guidance released by NIH in March 2017, which encouraged NIH investigators to use preprints and other interim research products to speed the dissemination of research and enhance the rigor of their work through public comments and new scientific collaborations….”
“NLM is preparing to launch a pilot project to test the viability of making preprints resulting from NIH-funded research available via PubMed Central (PMC). The primary goal of the NIH Preprint Pilot will be to explore approaches to increasing the discoverability of early NIH research results. The pilot will begin the week of June 8, 2020 and will run for a minimum of 12 months. Lessons learned during that time will inform future NLM efforts with preprints.
In its role as the repository for peer-reviewed manuscripts supported by NIH, PMC already makes available more than one million published papers resulting from NIH-supported research. Building on NIH guidance (NOT-OD-17-050) to investigators that encouraged the use of interim research products, such as preprints, to speed the dissemination and enhance the rigor of their work, NLM hopes this pilot will inform possible future steps to further accelerate discovery and access of papers that are developed with NIH funds and encourage the open and fast dissemination of NIH research results, when appropriate.
The pilot will initially focus on increasing the discoverability of preprints with NIH support relating to the current COVID-19 pandemic. NLM is leveraging the iSearch COVID-19 portfolio tool developed by the NIH Office of Portfolio Analysis to identify preprints reporting on COVID-19 research supported by the NIH intramural or extramural programs. This narrowly scoped first phase should allow NLM an opportunity to streamline workflows and refine the details of implementation with a set of articles for which there is a growing demand for accelerated access.
As curation and ingest workflows become scalable, NLM will expand the pilot to include preprints resulting from the broader spectrum of NIH research….”